Even when a stroke procedure goes perfectly, recovery doesn’t always follow.
The clot is removed.
The artery is open.
The scan looks clean.
But 90 days later, the patient still can’t walk independently.[1]
Here’s the thing — reopening the artery is not the same as restoring the brain.
The CHOICE 2 trial (ISC 2026) explains why this happens — and what might finally improve outcomes.[3]
What Happens After a “Successful” Thrombectomy?
Mechanical thrombectomy is the standard treatment for large vessel occlusion (LVO) stroke.
On paper, it works extremely well:
- The blocked artery is reopened
- Blood flow appears restored
But outcomes tell a different story:
- Over 50% of patients do not achieve excellent recovery
- Many remain dependent despite technically perfect procedures[1,2]
👉 This gap between technical success and real recovery is the problem.
The Real Issue: The No-Reflow Phenomenon
When a major artery is blocked:
- Clot fragments travel downstream
- Get lodged in tiny vessels (arterioles, capillaries)
- Continue to block blood flow at the micro level[1,2]
These blockages:
- Cannot be seen on standard angiography
- Persist even after successful thrombectomy
This is called the no-reflow phenomenon.
Even when the artery is open, the brain may still be under-perfused.
CT perfusion imaging confirms this — showing areas of ongoing hypoperfusion despite recanalization.[1]
What the CHOICE 2 Trial Did Differently
Instead of stopping after clot removal, researchers asked a sharper question:
What if we treat the clots that thrombectomy cannot reach?
Intervention:
After successful thrombectomy:
- Intra-arterial alteplase (0.225 mg/kg, max 20 mg)
- Delivered directly via catheter into the brain artery
- Targeting residual microemboli[3]
Study Design:
- 433 patients
- 14 stroke centers (Spain)
- All with successful recanalization (eTICI ≥ 2b50)[3]
Two groups:
- Standard care
- Standard care + intra-arterial alteplase
Results That Actually Matter to Patients
This wasn’t a marginal improvement — it was meaningful:
- 57.5% achieved excellent recovery (mRS 0–1) with alteplase
- 42.5% in standard care
- +15% absolute improvement (p=0.002)[3]
At the same time:
- Microvascular hypoperfusion reduced significantly
- 28.6% vs 50.5%
- No significant increase in symptomatic brain bleeding[3]
👉 This validates the core idea: Fixing microcirculation improves real-world recovery.
Why This Changes Stroke Treatment Thinking
Until now, success meant:
- The artery is open
But CHOICE 2 shows:
- The brain must actually receive blood
Because recovery depends on:
- Tissue survival
- Oxygen delivery
- Functional preservation
Not just imaging.
Expert Insight (Clinical Perspective)
In real-world stroke care, this explains a common frustration:
“We open the artery, but the patient doesn’t recover the way we expect.”
What this really means is:
- Large vessel → fixed
- Microcirculation → still compromised
CHOICE 2 bridges that gap.
Important Caveats (Don’t Skip This)
This is not a universal protocol yet.
The evidence is mixed:
- Neutral trials: POST-UK, POST-TNK, ATTENTION-IA
- Positive trials: CHOICE 1, ANGEL-TNK, PEARL[1,2]
CHOICE 2 is:
- The largest positive trial so far
- But not the final word
Safety Signal:
- Mortality:
- 12.1% (alteplase) vs 6.4% (control)
- Likely influenced by unusually low control mortality
- Still needs careful interpretation[3]
Current Guidelines (What Doctors Actually Follow)
- AHA/ASA 2026: Class IIb recommendation[4]
Meaning:
- May be considered in selected patients
- Not standard for everyone
Best Candidates:
- Evidence of microvascular hypoperfusion
- No contraindication to thrombolytics
- Moderate stroke severity
What Patients and Families Should Understand
If recovery feels incomplete after thrombectomy — this is why.
Stroke damage is not just:
- A blocked artery
It’s also:
- Microvascular injury
- Brain tissue damage
- Delayed recovery processes
Where Rehabilitation Becomes Critical
Even with advanced treatments, recovery still depends on:
- Physiotherapy
- Speech and cognitive therapy
- Structured rehabilitation programs
Because:
👉 Restoring blood flow starts recovery — rehabilitation completes it.
Key Takeaway
Opening the artery is step one.
Restoring blood flow at the micro level is what truly determines recovery.
CHOICE 2 moves stroke care closer to that goal.
FAQ:
Why do stroke patients not recover after successful thrombectomy?
Because small blood vessels in the brain may remain blocked even after the main artery is reopened. This is called the no-reflow phenomenon.
What is the CHOICE 2 trial in stroke treatment?
CHOICE 2 is a 2026 clinical trial that tested intra-arterial alteplase after thrombectomy to improve microcirculation and recovery outcomes.
Does alteplase improve stroke recovery after thrombectomy?
Yes, in the CHOICE 2 trial, it improved excellent stroke recovery rates by 15% without increasing major bleeding risk.
Is intra-arterial alteplase standard treatment after thrombectomy?
No. Current guidelines (AHA/ASA 2026) say it may be used in selected patients, not routinely.
This trial changes how we should think about what ‘successful’ thrombectomy means. Opening the artery is step one — perfusing the brain is the actual goal.
